

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

INSIDE INFORMATION
NMPA OF CHINA GRANTS NDA APPROVAL TO DTCP INFANT

This announcement is made by CanSino Biologics Inc. (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

The Company is pleased to announce that the National Medical Products Administration of China has granted new drug application (the “**NDA**”) approval to the Diphtheria, Tetanus and Pertussis (Acellular, Three Components) Combined Vaccine, Adsorbed (the “**DTcP**”) for infants (below 2 years old) (the “**DTcP Infant**”, trade name: Tripecia®) developed by the Company.

The manufacturing process of the co-purified diphtheria, tetanus and acellular pertussis vaccine currently available in China involves the use of a co-purification process for the pertussis antigens. As a diphtheria, tetanus and acellular pertussis (components) vaccine, each pertussis antigen of the DTcP Infant can be purified separately and formulated in a defined ratio, thus ensuring batch-to-batch consistency of product quality and making the product quality more stable.

The Company’s DTcP Infant is the first diphtheria, tetanus and acellular pertussis (components) vaccine to be launched in China. The development of DTcP Infant establishes the foundation for the further development of the absorbed diphtheria, tetanus and acellular pertussis (components) combined vaccine (for people aged six years old and above), as well as combined vaccine based on the DTcP components.

The Company’s DTcP Infant is the first product within the Company’s diphtheria, tetanus and acellular pertussis (components) vaccine portfolio to obtain NDA approval. The Company has accumulated relevant experience in clinical development, quality control, and large-scale manufacturing, which will facilitate the launch process of other vaccine candidates in the portfolio. At the same time, the launch of DTcP Infant will enrich and optimize the Company’s commercial product portfolio, which will be conducive to enhancing the Company’s brand recognition in the end market.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, April 12, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.